Gábor Mező Selected Research

Colonic Neoplasms (Colon Cancer)

9/2019	Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
9/2019	Apoptotic Effects of Drug Targeting Conjugates Containing Different GnRH Analogs on Colon Carcinoma Cells.
8/2019	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
1/2018	Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
1/2017	NGR-peptide-drug conjugates with dual targeting properties.
1/2014	Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate.
6/2012	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gábor Mező Research Topics

Disease

42	Neoplasms (Cancer) 02/2024 - 01/2012
7	Breast Neoplasms (Breast Cancer) 12/2023 - 01/2012
7	Colonic Neoplasms (Colon Cancer) 09/2019 - 06/2012
5	Melanoma (Melanoma, Malignant) 02/2024 - 02/2015
5	Neoplasm Metastasis (Metastasis) 12/2023 - 03/2015
5	Prostatic Neoplasms (Prostate Cancer) 02/2023 - 01/2012
4	Colorectal Neoplasms (Colorectal Cancer) 09/2019 - 01/2016
3	Carcinoma (Carcinomatosis) 10/2019 - 01/2014
2	Hypoxia (Hypoxemia) 04/2024 - 01/2020
2	Reperfusion Injury 04/2024 - 03/2022
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 06/2020
2	Tics (Tic) 09/2019 - 11/2018
2	Fibrosarcoma 01/2018 - 01/2017
1	Peripheral Arterial Disease 04/2024
1	Adenocarcinoma 03/2024
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2023
1	Glioblastoma (Glioblastoma Multiforme) 02/2023
1	Ovarian Neoplasms (Ovarian Cancer) 05/2022
1	Diabetic Retinopathy (Retinopathy, Diabetic) 03/2022
1	Ischemia 03/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Squamous Cell Carcinoma of Head and Neck 10/2019
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2019
1	Necrosis 09/2018

Drug/Important Bio-Agent (IBA)

24	Peptides (Polypeptides)IBA 03/2024 - 06/2012
17	Daunorubicin (Cerubidine)FDA LinkGeneric 03/2024 - 06/2012
15	gonadotropin-releasing hormone-IIIIBA 05/2022 - 01/2012
13	Gonadotropin-Releasing Hormone (GnRH)FDA Link 05/2022 - 01/2013
11	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 05/2022 - 01/2012
8	CD13 Antigens (Alanine Aminopeptidase)IBA 04/2024 - 03/2015
8	Cytostatic AgentsIBA 02/2023 - 01/2012
7	IntegrinsIBA 01/2023 - 03/2015
4	RadiopharmaceuticalsIBA 08/2023 - 01/2020
4	LigandsIBA 02/2023 - 09/2018
4	Protein Isoforms (Isoforms)IBA 07/2020 - 01/2017
4	Hormones (Hormone)IBA 01/2016 - 01/2012
3	OximesIBA 02/2024 - 01/2016
3	asparagine-glycine-arginineIBA 08/2023 - 01/2017
3	68Ga-NOTA-c(NGR)IBA 03/2022 - 01/2020
3	Antineoplastic Agents (Antineoplastics)IBA 02/2021 - 01/2013
3	NGR peptideIBA 01/2021 - 01/2017
2	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 04/2024 - 11/2020
2	EnzymesIBA 02/2023 - 05/2012
2	4-azidobenzylcarazolol (pABC)IBA 01/2023 - 05/2022
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2021 - 05/2012
2	hydroxide ionIBA 07/2020 - 06/2020
2	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 01/2020 - 03/2015
2	Proteins (Proteins, Gene)FDA Link 09/2019 - 01/2014
2	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 06/2012
2	Volatile Fatty AcidsIBA 01/2018 - 10/2012
2	Peptide Hormones (Polypeptide Hormones)IBA 01/2018 - 04/2013
2	His(5)-Trp(7)-Tyr(8)- LHRHIBA 01/2017 - 05/2015
2	thiazolyl blueIBA 04/2013 - 06/2012
1	Glucose (Dextrose)FDA LinkGeneric 04/2024
1	Phenylalanine (L-Phenylalanine)FDA Link 03/2024
1	HydrogelsIBA 02/2024
1	Type 1 Melanocortin ReceptorIBA 01/2024
1	Melanocyte-Stimulating Hormones (MSH)IBA 01/2024
1	Cell Surface ReceptorsIBA 01/2024
1	1,2-distearoylphosphatidylethanolamine (DSPE)IBA 12/2023
1	Liposomes (Liposome)IBA 12/2023
1	Bombesin Receptors (Bombesin Receptor)IBA 02/2023
1	BombesinIBA 02/2023
1	Angiopep-2IBA 02/2023
1	Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)IBA 02/2023
1	glycylleucine (Leu-Gly)IBA 01/2023
1	glycylproline (Gly-Pro)IBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 01/2023
1	Therapeutic UsesIBA 01/2023
1	monomethyl auristatin EIBA 01/2023
1	Cathepsin BIBA 05/2022
1	serum P-component (CIt)IBA 05/2022
1	DipeptidesIBA 05/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 05/2022
1	DiarylheptanoidsIBA 01/2022
1	Dosage Forms (Dosage Form)IBA 01/2022
1	AnthracyclinesIBA 02/2021
1	actinoninIBA 01/2021
1	Cyclic PeptidesIBA 01/2021
1	ubenimexIBA 01/2021
1	polypeptide CIBA 11/2020
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020
1	Staphylococcal Protein A (Protein A)IBA 01/2020
1	protoporphyrin IXIBA 10/2019
1	Photosensitizing Agents (Photosensitizers)IBA 10/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2019
1	Estrogen ReceptorsIBA 11/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2018
1	TIC10 compoundIBA 09/2018
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2018

Therapy/Procedure

23	Therapeutics 02/2024 - 05/2012
7	Drug Therapy (Chemotherapy) 02/2024 - 10/2012
2	Intravenous Injections 11/2020 - 01/2020
1	Tourniquets 04/2024
1	Ligation 03/2022
1	Subcutaneous Injections 11/2020
1	Photochemotherapy (Photodynamic Therapy) 10/2019